المؤلفون: Lidington, Emma, Vlooswijk, Carla, Stallard, Kate, Travis, Emily, Younger, Eugenie, Edwards, Penelope, Nandhabalan, Meera, Hunter, Nikki, Sarpal, Neelam, Flett, Denise, Din, Amy, Starling, Naureen, Larkin, James, Stanway, Susannah, Nobbenhuis, Marielle, Banerjee, Susana, Szucs, Zoltan, Darlington, Anne‐Sophie, Gonzalez, Michael, Sirohi, Bhawna

المصدر: European Journal of Cancer Care; Sep2021, Vol. 30 Issue 5, p1-11, 11p

مصطلحات موضوعية: CANCER patient psychology, FOCUS groups, CHILD care, RESEARCH methodology, ATTITUDE (Psychology), INTERVIEWING, WORK-life balance, GROUP identity, CANCER relapse, UNCERTAINTY, EXPERIENCE, QUALITATIVE research, PHENOMENOLOGY, SOCIAL isolation, NATIONAL health services, AGE factors in disease, DESCRIPTIVE statistics, TUMORS, THEMATIC analysis, FINANCIAL management, PSYCHOLOGICAL adaptation, BODY image, DISEASE risk factors, ADULTS

مصطلحات جغرافية: UNITED Kingdom

مستخلص: Objective: Adolescents and young adults with cancer face unique psychosocial and practical issues. However, patients across this group encounter different life experiences, cancer diagnoses and treatment settings given the tailored services for patients ages 15 to 24. Here, we qualitatively explore the psychosocial experiences and practical challenges of young adults (YAs) with cancer diagnosed between ages 25 and 39 in the United Kingdom. Methods: We invited YAs diagnosed with cancer in the 5 years prior to enrolment at participating sites to take part in semi‐structured interviews or focus groups. Transcripts were analysed using inductive thematic analysis. Two YA patients reviewed the results to ensure robustness. Results: Sixty‐five YAs with varied diagnoses participated. Participants struggled to balance work, childcare and financial solvency with treatment. The halt in family and work life as well as changes in image and ability threatened participants' identity and perceived 'normality' as a YA, however, these also stimulated positive changes. YAs experienced social isolation from friends and family, including children. Many struggled to cope with uncertainty around treatment outcomes and disease recurrence. Conclusion: The disruption of family and work life can lead to age‐specific issues in YAs diagnosed with cancer. Age‐tailored psychological and practical services must be considered. [ABSTRACT FROM AUTHOR]

: Copyright of European Journal of Cancer Care is the property of Hindawi Limited and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Roberts, Corran, Strauss, Victoria Y., Kopijasz, Sylwia, Gourley, Charlie, Hall, Marcia, Montes, Ana, Abraham, Jacinta, Clamp, Andrew, Kennedy, Richard, Banerjee, Susana, Folkes, Lisa K., Stratford, Michael, Nicum, Shibani

المصدر: British Journal of Cancer; Feb2020, Vol. 122 Issue 4, p483-490, 8p, 1 Diagram, 4 Charts, 1 Graph

مصطلحات موضوعية: THERAPEUTIC use of antineoplastic agents, PROTEINS, RESEARCH, OVARIAN tumors, RESEARCH methodology, CANCER relapse, EVALUATION research, MEDICAL cooperation, METHOTREXATE, COMPARATIVE studies, RESEARCH funding, SALVAGE therapy, BREAST tumors, DRUG resistance in cancer cells

مستخلص: Background: Tumour cells with BRCA1/2 gene mutations demonstrate increased sensitivity to platinum and poly (ADP-ribose) polymerase (PARP) inhibitors. 6-mercaptopurine (6MP) was found to selectively kill BRCA-defective cells in a xenograft model as effectively as the PARP inhibitor AG014699, even after these cells acquired resistance to a PARP inhibitor or cisplatin.Methods: This phase II single-arm trial investigated the activity of 6MP 55-75 mg/m2 per day, and methotrexate 15-20 mg/m2 per week in advanced breast or platinum-resistant ovarian cancer patients with a BRCA1/2 germline mutation, who had progressed after ≥1 previous line of chemotherapy. The primary outcome was objective response including stable disease (SD) as an assessment of clinical benefit rate (CBR), at 8 weeks, by RECIST v1.1. Secondary outcomes included overall survival (OS) and progression-free survival (PFS).Results: In total, 67 evaluable patients were recruited; 55 ovarian and 11 breast cancer patients. In total, 21 patients had SD (31%), one had a partial response (1.5%); CBR was 33% at 8 weeks. In total, 12/67 patients (18%) had SD at 16 weeks. In total, five ovarian cancer patients had SD for over 200 days. Median OS was 10.3 months (95% CI 6.9-14.5), median PFS 1.9 months (1.7-2.8).Conclusions: The overall activity of 6MP and methotrexate in these patients was low; however, there was a small group of patients who appeared to derive longer-term clinical benefit.Trial Registration: NCT01432145 http://www.ClinicalTrials.govTest. [ABSTRACT FROM AUTHOR]

: Copyright of British Journal of Cancer is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)